Centessa Pharmaceuticals plc
CNTA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 0.24 | -0.04 | 1.46 |
| FCF Yield | -1.29% | -2.99% | -1.94% | -1.15% |
| EV / EBITDA | -39.40 | -88.98 | -18.26 | -39.14 |
| Quality | ||||
| ROIC | -11.97% | -6.44% | -14.51% | -8.05% |
| Gross Margin | 0.00% | 100.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 1.06 | 0.45 | 2.19 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,466,112.07% | 2,466,112.07% | 2,466,112.07% | -100.00% |
| Free Cash Flow Growth | 60.56% | -33.75% | -99.79% | 47.21% |
| Safety | ||||
| Net Debt / EBITDA | -1.59 | -0.59 | 2.50 | 7.84 |
| Interest Coverage | -18.95 | -10.70 | -30.08 | -18.15 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,240.22 | 316.22 | 2,930.84 | -2,809.62 |